Background and Purpose-Citicoline sodium (cytidine-5Ј-diphosphocholine) has been shown previously to reduce ischemic injury in focal central nervous system models. Intracerebral hemorrhage (ICH) appears to be associated with an area of edema and ischemic injury surrounding the hematoma that may be reduced by neuroprotective therapy. The present study was designed to test whether treatment with citicoline reduces ischemic injury and improves functional neurological outcome in an experimental model of ICH. Methods-In 68 Swiss albino mice (26 to 36 g), ICH was induced by collagenase injection into the caudate nucleus.
P rimary intracerebral hematoma (ICH) is a major clinical problem, accounting for 15% of all acute stroke hospitalizations. Currently, there is no medical therapy available for these patients, with options being limited to supportive care or invasive neurosurgical evacuation. 1 There is a 35% mortality rate in patients with moderately sized ICH, with additional significant disability in many of the survivors. 2 Because ICH is an exclusion in the majority of ongoing acute stroke trials, it is unlikely that any medical therapy will be available in the near future. The damage induced by an ICH appears to be related to a combination of factors. There is a component of direct mechanical disruption from the hematoma. However, some of the surrounding injury also occurs secondary to edema formation and ischemia. 3, 4 Experimental studies have demonstrated a significant area of ischemia that surrounds the hematoma (penumbra). 5, 6 There is also a large area of edema, presumably mediated by glutamate release and free radical generation. 7 It is therefore possible that agents that reduce ischemic stroke injury may also be beneficial in ICH.
Citicoline (cytidine-5-diphosphocholine or CDPcholine) is an essential precursor for the synthesis of phosphatidylcholine, a key component of cell membranes.
See Editorial Comment, page 2140
The exogenous administration of citicoline has been shown in animal models 8, 9 to reduce this cell membrane breakdown, leading to increased synthesis of phosphatidylcholine and decreased levels of free fatty acids. The use of citicoline treatment has been shown to be beneficial in several animal models of ischemia or hypoxia, 10 -17 including recent studies with reversible focal occlusion. 18, 19 These studies have found that citicoline treatment decreases free fatty acid concentration, improves neurological signs, decreases neurological deficits, restores animal learning performance, reduces glutamate-mediated injury, preserves phosphatidylcholine levels, and improves neuronal survival. Because citicoline treatment appears to protect neuronal tissue in the penumbra, it is likely that this therapy would prove beneficial in reducing the ischemiarelated injury component of ICH. In the current study, we used a mouse adaptation of the collagenase hemorrhage model 20 to test whether treatment with citicoline reduces ischemic injury and improves functional neurological outcome in an ICH model that approximates clinical ICH.
Materials and Methods

Experimental Design
All animal procedures were approved by the Oregon Health Sciences University Institutional Review Board and are in accordance with guidelines published by the National Institutes of Health for animal use. Sixty-eight male Swiss albino mice weighing 26 to 36 g were anesthetized with halothane/O 2 administered by an inhalation mask. Citicoline sodium (lot # 3D0397) was supplied by Interneuron Pharmaceuticals, Inc. The placebo was sterile saline. Upon arrival, citicoline was stored at room temperature in a desiccator. Animals were divided randomly into 2 groups receiving either placebo (0.1 mL sterile 0.9% saline) or citicoline (500 mg/kg) (0.1 mL). This 500-mg/kg dose has been found to be beneficial in the rat MCA occlusion model 18, 19 Citicoline or placebo was administered intraperitoneally immediately before collagenase injection and at 24 and 48 hours (for a total of 3 doses). However, since it takes several hours for the hematoma to develop, the animals were actually treated with citicoline before the ICH occurred.
ICH Model
A 0.5-L glass syringe filled with 0.9% saline was connected to PE 10 tubing and used to draw up the collagenase. A 30-gauge, 4-mm needle attached to the tubing was implanted into the caudate nucleus/globus pallidus (Stotnick and Leonard Atlas) at the coordinates AP-1.0, L-3.0, S-4.0, relative to stereotaxic zero. Bacterial collagenase (type VII-S, Sigma Chemical Co; 0.075 U in 0.5 L volume) was injected over 2 minutes, with the needle left in place for an additional 3 minutes after injection. The mice were allowed to recover from surgery in a warm environment over a 3-hour period. Core animal temperature was maintained at 37Ϯ0.5°during this time. Animals began to exhibit neurological signs of an ICH within 60 minutes At 24 and 48 hours after ischemia, each mouse was scored neurologically for focal deficits with use of a 28-point neurological scoring system (see Table 1 ). 21 Two investigators, blinded to the identity of the individual animals, scored the animals independently, and the scores were averaged. Scoring was performed immediately before the daily citicoline/placebo injection. In addition, the weight of each mouse was recorded daily.
Tissue Preparation
At 54 hours, 6 hours after the final neurological scoring, each animal was anesthetized with a 0.15-mL IP injection of ketamine (28 mg/mL), xylazine (2.8 mg/mL), and acepromazine (0.06 mg/mL) and perfused transcardially with saline for 20 seconds (10 mL), followed by 10% phosphate buffered formalin for 5 minutes (100 mL). Brains were then removed and placed in 7-mL scintillation vials containing 10% phosphate buffered formalin for postfixation overnight at 4°C. The formalin in each vial was replaced by 15% sucrose containing 0.05% sodium azide and stored at 4°C until sectioning occurred.
Whole brains were mounted on a freezing microtome, and tissue was embedded in OCT Tissue-Tek (#4583, Miles Inc). Frozen tissue was cut in 50-m sections, with 2 sections obtained every 0.5. Approximately 10 to 14 sections per brain were mounted on chrome-albumin-jelly slides. Slides were dried at room temperature overnight and then baked in a 37°C oven for a minimum of 6 hours. Sections were stained with Luxol Fast Blue (ICN Biomedicals Inc) and counterstained with Cresyl Violet Acetate (Eastman Kodak Co) to differentiate between the hematoma and the area of ischemia/ edema around the hematoma. An NIH image analysis system with 1200-dpi flatbed scanner was used to measure the lesion areas. The following areas were identified on each section: total ipsilateral and contralateral hemisphere area, area of hematoma, total affected area (total lesion), and surrounding area of ischemic injury (ischemia plus edema; total lesion area minus hematoma area) (see the Figure) . Volumes in cubic millimeters were calculated by multiplying the 0.5-mm slice thickness by the measured areas. To partially correct for effects of edema, all lesion areas were also expressed as percent of ipsilateral hemisphere involved. Results were analyzed with Section of mouse tissue showing determination of the hematoma (H) and ischemic injury (I) areas. 
Results
A total of 68 animals were randomized and treated. The successful placement of the needle was confirmed by the location and size of the hemorrhage as well as the animals' exhibiting focal findings. The results of the histological volume analysis are summarized in The clinical neurological focal scores and animal weights at 24 and 48 hours are summarized in Table 3 . Compared with placebo, citicoline-treated animals showed improved neurological function at both time points. The average total focal score at 24 hours for the citicoline group was 11.1Ϯ2.1 (meanϮSD) versus 12.8Ϯ2.5 for placebo (tϭ3.0; Pϭ0.003). At 48 hours, the average total focal score for the citicoline group was 10.4Ϯ2.0 versus 12.1Ϯ2.4 for placebo (tϭ3.2; Pϭ0.002). There was no significant difference between the groups in body weight over the 48-hour time period.
Discussion
Our study shows that treatment with citicoline in experimental intracerebral hemorrhage improves neurological functional outcome and reduces the volume of the ischemic injury surrounding the hematoma. To our knowledge, this is the first study to document both improved functional outcome and a reduction in ischemic injury volume in an experimental intracerebral hemorrhage model. It is also the first report of adapting the collagenase ICH model for mice.
The exact neuroprotective mechanism of citicoline in this study, or even in the treatment of central nervous system ischemic injury, is not known. Possible mechanisms that are supported by previous studies include a reduction in free fatty acids and free radical release, neuronal membrane stabilization, decrease in glutamate toxicity, and improved neuronal survival. 8 -17,20,22-25 Because previous studies have documented a significant ischemic area surrounding ICH, 4, 6, 26 it is likely that the same neuroprotective mechanisms seen in ischemia are also operative in the current study. In our study, the color and morphological appearance of the ischemic area surrounding the hematoma on histological evaluation is identical to the area of ischemic injury that we see in a focal MCA occlusion model in the mouse. 21 The reduction in the size of the ischemic area seen with citicoline treatment is likely a combination of an actual reduction in ischemic tissue with a decrease in edema. At 48 hours it is impossible to separate the relative amounts of ischemia and edema, and a long-term (1-month) study is needed to determine whether citicoline actually affects final infarct size. However, since much of the mortality and early morbidity in ICH occurs within 48 hours, an agent that reduces early lesion volume may have significant clinical benefit. This discussion has been added to the study.
Several prior experimental studies in the rat have shown that various pharmacological agents may produce neuroprotection and improve outcome in ICH. Lyden et al 27 used a quantal bioassay to demonstrate that the GABA agonist muscimol was neuroprotective in a rat collagenase ICH model. In this study, varying quantities of collagenase were injected, and it was found that animals treated with muscimol were able to tolerate larger amounts of collagenase and still exhibit normal neurological function. The investigators also found that muscimol treatment helped preserve the volume of the basal ganglia and white matter at 72 hours. Rosenburg and Navratil 28 found that treatment with the calcium channel blocker emopamil significantly reduced water content in the posterior region of the brain, but they did not find a reduction in edema at the hemorrhage site. Effects on neurological function were not assessed in this study. The same group also found that administration of atrial natriuretic peptide also reduced brain edema at 24 hours in a rat model of ICH. 29 Finally, Sinar et al 26 found that pretreatment with nimodipine produced a reduction in the amount of ischemic damage and an improvement in surrounding cerebral blood flow in an autologous hemorrhagic clot model in the rat. The results of these experimental studies suggest that it is possible to reduce ICH injury through use of neuroprotective strategies.
In clinical stroke treatment trials, ICH is an exclusion for the majority of the ongoing studies. A few trials 30 do allow a small number of patients to be included if the CT scan is obtained after treatment has been initiated. Citicoline has shown promise in reducing neurological deficit in clinical ischemic stroke, 31 and further work confirming this efficacy is currently in progress. Since citicoline, unlike thrombolytics, can be administered in the field before a CT scan and has minimal side effects, it appears to be an ideal candidate for medical therapy of ICH.
Conclusions
In this experimental model of ICH, citicoline treatment significantly reduced the area of ischemic injury surrounding the hematoma and improved functional outcome at 2 days. No adverse effects of citicoline were observed in this animal model. These results support future clinical efficacy trials.
